193 related articles for article (PubMed ID: 12932387)
1. Imatinib for systemic mast-cell disease.
Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
3. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107.
von Bubnoff N; Gorantla SH; Kancha RK; Lordick F; Peschel C; Duyster J
Leukemia; 2005 Sep; 19(9):1670-1. PubMed ID: 16015383
[No Abstract] [Full Text] [Related]
4. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Vega-Ruiz A; Cortes JE; Sever M; Manshouri T; Quintás-Cardama A; Luthra R; Kantarjian HM; Verstovsek S
Leuk Res; 2009 Nov; 33(11):1481-4. PubMed ID: 19193436
[TBL] [Abstract][Full Text] [Related]
5. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
[TBL] [Abstract][Full Text] [Related]
7. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
8. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
9. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
[TBL] [Abstract][Full Text] [Related]
10. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
Nakagomi N; Hirota S
Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
[TBL] [Abstract][Full Text] [Related]
11. Skin lesions and mast cells.
Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
[No Abstract] [Full Text] [Related]
12. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
13. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Verstovsek S; Akin C; Manshouri T; Quintás-Cardama A; Huynh L; Manley P; Tefferi A; Cortes J; Giles FJ; Kantarjian H
Leuk Res; 2006 Nov; 30(11):1365-70. PubMed ID: 16797704
[TBL] [Abstract][Full Text] [Related]
14. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M
Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C
Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489
[TBL] [Abstract][Full Text] [Related]
16. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.
Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G
J Clin Oncol; 2006 Feb; 24(4):e6-7. PubMed ID: 16446324
[No Abstract] [Full Text] [Related]
17. Systemic mastocytosis: current classification and novel therapeutic options.
Barbie DA; Deangelo DJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
Lim KH; Pardanani A; Butterfield JH; Li CY; Tefferi A
Am J Hematol; 2009 Dec; 84(12):790-4. PubMed ID: 19890907
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
20. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
